Products for Research Use Only
RegisterLogin

Adezmapimod

CAT: 0804-HY-10256-02Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10256-02Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator[1][2][3].
CAS Number
152121-47-6
Product Name Alternative
SB 203580; RWJ 64809
UNSPSC
12352005
Hazard Statement
H302, H319
Target
Autophagy; HSP; Mitophagy; Organoid; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/SB-203580.html
Purity
99.96
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=S(C1=CC=C(C2=NC(C3=CC=C(F)C=C3)=C(C4=CC=NC=C4)N2)C=C1)C
Molecular Formula
C21H16FN3OS
Molecular Weight
377.43
Precautions
H302, H319
References & Citations
[1]Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351 (Pt 1) :95-105.|[2]Lali FV, et al. The pyridinyl imidazole inhibitor SB203580 blocks phosphoinositide-dependent protein kinase activity, protein kinase B phosphorylation, and retinoblastoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 mitogen-activated protein kinase. J Biol Chem. 2000 Mar 10;275 (10) :7395-402.|[3]Leelahavanichkul K, et al. A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis. Mol Oncol. 2014 Feb;8 (1) :105-18.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
P38 MAPK; p38β
Citation 01
AAPS PharmSciTech. 2022 Mar 14;23 (3) :83.|ACS Biomater Sci Eng. 2021 Jul 12;7 (7) :3399-3408.|ACS Pharmacol Transl Sci. 2025 Jul 7;8 (8) :2612-2629.|Acta Biochim Biophys Sin (Shanghai) . 2025 May 15.|Acta Pharm Sin B. 2024 May 18.|Acta Pharmacol Sin. 2017 Aug;38 (8) :1120-1128.|Acta Pharmacol Sin. 2022 Sep;43 (9) :2289-2301.|Acta Pharmacol Sin. 2025 Jun 11.|Acta Physiol (Oxf) . 2018 Feb;222 (2) .|Acupunct Med. 2021 Dec;39 (6) :708-715.|Adv Sci (Weinh) . 2024 Dec 30:e2413128.|Adv Sci (Weinh) . 2024 Oct 28:e2406979.|Adv Sci (Weinh) . 2025 Feb 7:e2413324.|Aging (Albany NY) . 2021 May 11;13 (9) :12780-12799.|Aging (Albany NY) . 2021 May 6;13 (10) :13788-13806.|Aging (Albany NY) . 2022 Aug 5;14 (15) :6149-6168.|Aging Cell. 2020 Oct;19 (10) :e13217.|Aging Cell. 2022 Jul;21 (7) :e13659.|Aging. 2020 Nov 20;12 (23) :24208-24218.|Am J Chin Med. 2025;53 (7) :2277-2305.|Am J Physiol Cell Physiol. 2018 Aug 1;315 (2) :C225-C235.|Am J Physiol Cell Physiol. 2022 Jul 1;323 (1) :C133-C144.|Am J Physiol Cell Physiol. 2023 Nov 1;325 (5) :C1228-C1243.|Am J Transl Res. 2019 Feb 15;11 (2) :806-818.|Am J Transl Res. 2020 Feb 15;12 (2) :478-492.|Am J Transl Res. 2020 Jul 15;12 (7) :3577-3595. |Andrology. 2025 Jun 16.|Ann Transl Med. 2019 Dec;7 (23) :758.|Anticancer Drugs. 2025 Apr 1;36 (4) :319-327.|Antioxidants (Basel) . 2021 Jun 29;10 (7) :1049.|Antioxidants (Basel) . 2021 Mar 13;10 (3) :443.|Antioxidants (Basel) . 2022 Mar 31;11 (4) :682.|Antioxidants (Basel) . 2023 Mar 30;12 (4) :838.|Antioxidants (Basel) . 2024 Mar 13;13 (3) :343.|Antiviral Res. 2022 Dec:208:105463.|Apoptosis. 2021 Apr;26 (3-4) :195-208.|Aquaculture. 2023 Dec 15, 577, 739927.|Aquaculture. 2025 Sep 15.|Aquat Toxicol. 2018 Jun:199:116-126.|Arch Biochem Biophys. 2023 Jan 15:734:109486.|Arch Biochem Biophys. 2024 Dec 9:110255.|Arch Toxicol. 2023 Jun;97 (6) :1783-1794.|Arthritis Res Ther. 2025 May 31;27 (1) :118.|Artif Cell Nanomed B. 2019 Dec;47 (1) :3087-3093.|Artif Cells Nanomed Biotechnol. 2019 Dec;47 (1) :685-695.|Authorea. 2022.|Authorea. 2024 Jul 13.|Autophagy. 2020 Aug;16 (8) :1413-1435.|Autophagy. 2021 Nov;17 (11) :3592-3606.|Autophagy. 2025 Aug 6:1-17.|Bioact Mater. 2025 Nov 25:57:646-659.|Biochem Bioph Res Co. 2020 Oct 15;531 (2) :187-194.|Biochem Cell Biol. 2017 Feb;95 (1) :64-68.|Biochem Pharmacol. 2024 May:223:116194.|Biochem Pharmacol. 2025 Jun 6:239:117032.|Biochim Biophys Acta Mol Basis Dis. 2022 May 1;1868 (5) :166369.|Biochim Biophys Acta Mol Cell Res. 2021 Sep;1868 (10) :119083.|Biochim Biophys Acta Mol Cell Res. 2023 Oct;1870 (7) :119540.|Bioengineered. 2022 Apr;13 (4) :8747-8758.|Biol Pharm Bull. 2022 Aug 1;45 (8) :1061-1068.|Biol Trace Elem Res. 2024 Jun;202 (6) :2598-2615.|Biomaterials. 2018 Aug;175:19-29.|Biomaterials. 2024 Mar:305:122462.|Biomed Pharmacother. 2018 Dec:108:1294-1302.|Biomed Pharmacother. 2019 Dec;120:109489.|Biomed Pharmacother. 2020 Jan;121:109304.|Biomed Pharmacother. 2020 Mar;123:109752.|Biomed Pharmacother. 2020 Sep;129:110384.|Biomed Pharmacother. 2023 Sep:165:115231.|Biomed Pharmacother. 2024 Jun:175:116637.|Biomed Res Int. 2019 Jul 10:2019:5347804.|Biomed Res. 2017; 28 (8) : 3383-3386|Biomedicines. 2020 Nov 9;8 (11) :485.|Bioorg Med Chem. 2020 Jul 1;28 (13) :115547|bioRxiv. 2020 Jun.|bioRxiv. 2023 Aug 14.|bioRxiv. 2023 Mar 24.|bioRxiv. 2023 Sep 29:2023.09.27.559864.|bioRxiv. 2024 May 2.|bioRxiv. 2025 January 18.|bioRxiv. January 18, 2022.|Biosci Rep. 2020 May 29;40 (5) :BSR20193256.|BMC Cancer. 2023 Nov 14;23 (1) :1108.|BMC Complement Altern Med. 2019 Aug 29;19 (1) :233.|BMC Complement Med Ther. 2022 Apr 6;22 (1) :100.|BMC Immunol. 2023 Nov 8;24 (1) :43.|BMC Pulm Med. 2018 Nov 27;18 (1) :178.|Br J Pharmacol. 2018 Dec;175 (23) :4338-4352.|Br J Pharmacol. 2020 Nov;177 (22) :5046-5062.|Brain Behav Immun. 2024 Jul:119:36-50.|Brain Res Bull. 2021 Aug:173:162-173.|Brain Sci. 2023 Jul 11;13 (7) :1058.|Brain Sci. 2024 Apr 14, 14 (4), 380.|Can Respir J. 2022 Oct 10:2022:6879539.|Cancer Cell Int. 2025 Oct 14;25 (1) :349.|Cancer Commun (Lond) . 2021 Jan;41 (1) :62-78.|Cancer Lett. 2017 May 1:393:22-32.|Cancer Lett. 2025 Aug 29:633:218010.|Cancer Rep (Hoboken) . 2025 Mar;8 (3) :e70179.|Carbohydr Polym. 2019 Dec 1;225:115223.|Cell Commun Signal. 2021 Oct 11;19 (1) :103.|Cell Commun Signal. 2024 Feb 12;22 (1) :115.|Cell Commun Signal. 2024 Jun 3;22 (1) :307.|Cell Commun Signal. 2025 Jan 13;23 (1) :22.|Cell Commun Signal. 2025 Jan 8;23 (1) :14.|Cell Death Differ. 2017 Mar;24 (3) :492-499.|Cell Death Differ. 2019 Nov;26 (11) :2386-2399. |Cell Death Differ. 2020 Jun;27 (6) :1938-1951.|Cell Death Dis. 2016 Jun 23;7 (6) :e2273. |Cell Death Dis. 2021 Jun 2;12 (6) :570.|Cell Death Dis. 2021 Jun 7;12 (6) :582.|Cell Death Dis. 2021 Nov 27;12 (12) :1113.|Cell Death Dis. 2022 Jul 15;13 (7) :615.|Cell Death Dis. 2022 Nov 23;13 (11) :987.|Cell Death Dis. 2022 Oct 8;13 (10) :860.|Cell Death Dis. 2025 Apr 29;16 (1) :351.|Cell Death Dis. 2019 Jul 8;10 (7) :520.|Cell Death Dis. 2019 Mar 15;10 (4) :255.|Cell Death Discov. 2019 Aug 5:5:125.|Cell Death Discov. 2025 Feb 18;11 (1) :64.|Cell Immunol. 2024 Jun 17:401-402:104843.|Cell Immunol. 2024 Nov-Dec:405-406:104884.|Cell J. 2022 Dec 1;24 (12) :732-740.|Cell Microbiol. 2019 Sep;21 (9) :e13064.|Cell Mol Biol Lett. 2025 May 14;30 (1) :59.|Cell Mol Immunol. 2022 Nov;19 (11) :1263-1278.|Cell Mol Immunol. 2023 Feb;20 (2) :175-188.|Cell Mol Immunol. 2025 Jul;22 (7) :791-805.|Cell Physiol Biochem. 2018;46 (5) :1779-1792. |Cell Prolif. 2019 Nov;52 (6) :e12691.|Cell Prolif. 2021 Jan;54 (1) :e12933.|Cell Rep Med. 2024 Feb 20;5 (2) :101388.|Cell Rep Med. 2025 Jan 16:101922.|Cell Rep. 2020 Jan 14;30 (2) :497-509.e4. |Cell Rep. 2022 Dec 27;41 (13) :111891.|Cell Rep. 2022 Mar 15;38 (11) :110520.|Cell Res. 2020 Jul;30 (7) :574-589.|Cell Signal. 2016 Feb;28 (2) :81-93.|Cell Signal. 2019 Feb:54:17-26.|Cell Signal. 2020 Mar;67:109522.|Cell Signal. 2021 Sep:85:110060.|Cell Signal. 2025 Jan:125:111504.|Cell Signal. 2025 Jun 25:111962.|Cell Signal. 2025 Oct 18:112174.|Cells. 2022 Feb 18;11 (4) :723.|Chem Biodivers. 2019 Aug;16 (8) :e1900325.|Chem Biol Interact. 2021 Oct 1:348:109634.|Chem Res Toxicol. 2022 Mar 21;35 (3) :422-430.|Chem Sci. 2018 Jan 31;9 (10) :2674-2689.|Chemosphere. 2020 Oct;256:127038.|Chin Arch Otolaryngol Head Neck Surg. 2016,23 (01) :49-52.|Chin Herb Med. 2022 Sep 1;14 (4) :554-562.|Chin J Integr Med. 2024 Sep;30 (9) :818-825.|Chin J Nat Med. 2020 Oct;18 (10) :738-748.|Chin J Nat Med. 2023 Jan;21 (1) :36-46.|Chin Med. 2021 Jul 19;16 (1) :58.|Chin Med. 2025 Oct 5;20 (1) :159.|China Biotechnology. 2017, 37 (12) : 40-48.|Clin Mol Hepatol. 2023 Apr;29 (2) :465-481.|CNS Neurosci Ther. 2020 Sep;26 (9) :913-924.|Commun Biol. 2022 Jul 22;5 (1) :726.|Commun Biol. 2024 Jan 5;7 (1) :18.|Commun Biol. 2024 Nov 5;7 (1) :1438.|Connect Tissue Res. 2024 May 16:1-12.|Curr Issues Mol Biol. 2024 Dec 31;47 (1) :16.|Curr Issues Mol Biol. 2025 Apr 7;47 (4) :253.|Curr Res Food Sci. 2023 Jan 16:6:100447.|Curr Res Toxicol. 2024 Oct 24:7:100199.|Cytokine. 2021 Jun:142:155502.|Cytotechnology. 2026 Feb;78 (1) :3.|Dev Comp Immunol. 2022 Feb:127:104292.|Diabetes Metab Syndr Obes. 2021 Nov 12;14:4523-4534.|Dis Markers. 2018 Apr 17:2018:7413027.|DNA Cell Biol. 2024 Sep;43 (9) :474-481.|Drug Des Devel Ther. 2024 Nov 27:18:5445-5459.|Drug Dev Res. 2022 Nov;83 (7) :1683-1696.|Drug Dev Res. 2025 Nov;86 (7) :e70183.|Ecotoxicol Environ Saf. 2020 Mar 1;190:110133.|Ecotoxicol Environ Saf. 2023 Sep 15:263:115247.|Ecotoxicol Environ Saf. 2025 Jun 24:302:118576.|Elife. 2016 Apr 11;5:e14087.|EMBO Mol Med. 2023 Jan 11;15 (1) :e16373.|EMBO Mol Med. 2025 Mar;17 (3) :535-562.|EMBO Rep. 2021 Jul 5;22 (7) :e51678.|Endocrine. 2020 Apr;68 (1) :103-115.|Environ Int. 2020 Oct;143:105949.|Environ Pollut. 2020 Jan;256:113375.|Environ Pollut. 2021 Jan 1;268 (Pt B) :115748.|Environ Pollut. 2022 Dec 15:315:120234.|Environ Toxicol. 2021 Feb;36 (2) :276-286.|Environ Toxicol. 2023 Jan;38 (1) :90-100.|Environ Toxicol. 2023 Nov;38 (11) :2621-2631.|Environ Toxicol. 2025 Jan;40 (1) :88-100.|Eur Arch Otorhinolaryngol. 2019 Mar;276 (3) :767-774.|Eur J Integr Med. 2024 Sep 8.|Eur J Pharmacol. 2021 May 5:898:173982.|Eur J Pharmacol. 2021 Sep 5:906:174270.|Eur J Pharmacol. 2022 Jul 5:926:175034.|Eur J Pharmacol. 2025 Sep 15:1003:177897.|Eur Rev Med Pharmacol Sci. 2019 Aug;23 (3 Suppl) :1-8.|Exp Eye Res. 2023 Mar:228:109388.|Exp Physiol. 2021 Feb;106 (2) :438-449.|Exp Ther Med. 2020 Mar;19 (3) :1824-1834.|Exp Ther Med. 2020 Mar;19 (3) :2243-2251.|Exp Ther Med. 2021 Dec;22 (6) :1440.|Exp Ther Med. 2021 Dec;22 (6) :1461.|Exp Ther Med. 2021 May;21 (5) :468.|Exp Ther Med. 2022 Jan;23 (1) :11.|Exp Ther Med. 2023 Mar 14;25 (4) :188.|FASEB J. 2019 Feb;33 (2) :2435-2450. |FASEB J. 2020 Jun;34 (6) :8442-8458.|FASEB J. 2020 Nov;34 (11) :14892-14904.|FASEB J. 2025 Aug 31;39 (16) :e70945.|FASEB J. 2025 Mar 31;39 (6) :e70393.|FASEB J. 2025 Sep 30;39 (18) :e71045.|FEBS Open Bio. 2020 Mar;10 (3) :434-443.|Food Biosci. 2021, 101268.|Food Biosci. 7 May 2022, 101766.|Food Chem Toxicol. 2021 Feb:148:111925.|Food Chem Toxicol. 2022: 113550.|Food Chem Toxicol. 2023 Aug:178:113870.|Food Chem Toxicol. 2023 Jun:176:113784.|Food Chem Toxicol. 2024 Apr:186:114561.|Food Chem X. 2022 Apr 30;14:100321.|Food Funct. 2021 May 11;12 (9) :3898-3918.|Food Sci Anim Resour. 2024 Sep;44 (5) :1167-1180.|Food Sci Hum Wellness. 2025.|Food Sci Nutr. 2025 Feb 25;13 (3) :e4687.|Free Radic Biol Med. 2017 Nov:112:49-59.|Free Radic Biol Med. 2019 Nov 1:143:275-287.|Free Radic Biol Med. 2021 Dec;177:247-259.|Free Radic Res. 2025 May-Jul;59 (6-7) :518-530.|Front Biosci (Landmark Ed) . 2023 Dec 1;28 (12) :325.|Front Biosci (Landmark Ed) . 2025 Mar 6;30 (3) :36255.|Front Cell Dev Biol. 2021 Feb 11:9:570451.|Front Cell Dev Biol. 2021 Jun 18;9:659389.|Front Cell Dev Biol. 2021 Nov 5:9:741060.|Front Cell Infect Microbiol. 2019 Jul 15:9:253.|Front Endocrinol. 2021 Mar 12:12:629554.|Front Immunol. 2017 Oct 10:8:1278.|Front Immunol. 2018 Dec 7:9:2854.|Front Immunol. 2018 Jun 5:9:1225.|Front Immunol. 2021 Apr 1:12:584097.|Front Immunol. 2021 Jul 28:12:688294.|Front Immunol. 2021 Jul 7:12:692286.|Front Oncol. 2020 Sep 30;10:523577.|Front Pharmacol. 2021 Apr 30:12:644886.|Fundam Clin Pharmacol. 2020 Oct;34 (5) :591-602.|Future Sci OA. 2025 Dec;11 (1) :2455906.|Genes Dis. 2025 Nov 6.|Genome Biol. 2023 Feb 1;24 (1) :20.|Glia. 2023 Jul;71 (7) :1648-1666.|Haematologica. 2020 Jan;105 (1) :124-135. |Harvard Medical School LINCS LIBRARY|Hepatology. 2023 Feb 1;77 (2) :456-465.|Hum Mol Genet. 2017 Sep 15;26 (18) :3553-3563.|Immun Inflamm Dis. 2024 Sep;12 (9) :e70012.|Infect Immun. 2021 Feb 16;89 (3) :e00680-20.|Inflammation. 2024 Sep 20.|Int Immunopharmacol. 2019 Dec;77:105940.|Int Immunopharmacol. 2019 Jul:72:252-257.|Int Immunopharmacol. 2020 Jun;83:106473.|Int Immunopharmacol. 2020 Nov;88:106823.|Int Immunopharmacol. 2020 Nov;88:106949.|Int Immunopharmacol. 2021 Dec;101 (Pt A) :108264.|Int Immunopharmacol. 2022 Jun:107:108643.|Int Immunopharmacol. 2023 Jul:120:110287.|Int Immunopharmacol. 2024 Jan 25:127:111355.|Int Immunopharmacol. 2024 Jul 1:138:112592.|Int Immunopharmacol. 2024 Sep 19;142 (Pt B) :113151.|Int Immunopharmacol. 2025 Apr 10:155:114550.|Int Immunopharmacol. 2025 Apr 4:151:114322.|Int Immunopharmacol. 2025 Jan 17:148:113972.|Int Immunopharmacol. 2025 May 28:159:114959.|Int Immunopharmacol. 2026 Jan 1;168 (Pt 2) :115903.|Int J Biochem Cell Biol. 2021 Aug:137:106036.|Int J Biochem Cell Biol. 2021 Jul:136:106003.|Int J Biochem Cell Biol. 2024 Apr:169:106549.|Int J Biol Macromol. 2020 May 1;150:261-280.|Int J Biol Macromol. 2023 Feb 1:227:45-57.|Int J Biol Macromol. 2025 Aug 25:326:147087.|Int J Biol Sci. 2022 Jan 16;18 (4) :1363-1380.|Int J Biol Sci. 2022 May 1;18 (8) :3167-3177.|Int J Biol Sci. 2023 Sep 4;19 (15) :4744-4762.|Int J Clin Exp Med. 2017;10 (9) :13542-13549.|Int J Food Sci Tech. 2024 Jul 18.|Int J Immunopathol Pharmacol. 2024 Jan-Dec:38:3946320241249445.|Int J Mol Med. 2021 Jan;47 (1) :243-255.|Int J Mol Med. 2023 Aug;52 (2) :67.|Int J Mol Med. 2026 Jan;57 (1) :21.|Int J Mol Sci. 2022 Mar 25;23 (7) :3589.|Int J Mol Sci. 2022 Nov 16;23 (22) :14141.|Int J Mol Sci. 2022 Nov 25;23 (23) :14730.|Int J Mol Sci. 2022 Oct 13;23 (20) :12219.|Int J Mol Sci. 2024 Dec 27;26 (1) :143.|Int J Nanomedicine. 2024 Jul 3:19:6659-6676.|Int J Radiat Oncol Biol Phys. 2023 Apr 1;115 (5) :1229-1243.|Invest Ophthalmol Vis Sci. 2020 Jul 1;61 (8) :28.|iScience. 2024 Sep 12;27 (10) :110873.|iScience. 2025 Apr 22;28 (5) :112502.|iScience. 2025 Apr 24;28 (6) :112501.|iScience. 2025 Aug 19;28 (9) :113396.|iScience. 2025 Nov 17.|J Agric Food Chem. 2018 Jun 27;66 (25) :6317-6325. |J Agric Food Chem. 2022 Apr 13;70 (14) :4328-4341.|J Agric Food Chem. 2023 Feb 8.|J Agric Food Chem. 2023 Jun 21;71 (24) :9381-9390.|J Agric Food Chem. 2024 Jul 31;72 (30) :16739-16748.|J Agric Food Chem. 2024 Jun 7.|J Agric Food Chem. 2024 Nov 20;72 (46) :25601-25619.|J Appl Toxicol. 2025 Sep;45 (9) :1694-1704.|J Asian Nat Prod Res. 2020 Sep;22 (9) :850-863.|J Biol Chem. 2019 Apr 19;294 (16) :6531-6549.|J Biomed Sci. 2025 Jan 6;32 (1) :5.|J Cardiothorac Surg. 2021 May 10;16 (1) :127.|J Cell Biochem. 2018 Nov;119 (10) :8450-8459.|J Cell Biochem. 2019 May;120 (5) :8561-8569.|J Cell Biol. 2021 Feb 1;220 (2) :e201911025.|J Cell Mol Med. 2018 Nov;22 (11) :5450-5467.|J Cell Mol Med. 2019 May;23 (5) :3357-3368.|J Cell Mol Med. 2020 Aug;24 (16) :9300-9312.|J Cell Mol Med. 2020 Sep;24 (18) :10935-10945.|J Cell Physiol. 2019 Dec;234 (12) :23302-23314.|J Cell Physiol. 2020 Oct;235 (10) :6563-6573.|J Clin Endocrinol Metab. 2021 Jan 23;106 (2) :337-350.|J Clin Neurosci. 2020 Aug;78:365-370.|J Dairy Sci. 2020 Dec;103 (12) :11636-11652.|J Dairy Sci. 2025 Jul;108 (7) :6617-6633.|J Dairy Sci. 2025 Mar;108 (3) :2152-2168.|J Dent. 2025 Oct:161:105978.|J Endocrinol Invest. 2025 Jan;48 (1) :67-80.|J Endod. 2018 May;44 (5) :751-758.|J Ethnopharmacol. 2021 Nov 15:280:114414.|J Ethnopharmacol. 2024 Jul 15:118580.|J Ethnopharmacol. 2024 Jun 14:118421.|J Ethnopharmacol. 2024 May 10:325:117755.|J Ethnopharmacol. 2024 May 16:118355.|J Ethnopharmacol. 2025 Aug 29:352:120267.|J Ethnopharmacol. 2025 Jul 11;353 (Pt A) :120282.|J Eur Acad Dermatol Venereol. 2020 Apr;34 (4) :862-872.|J Exp Clin Cancer Res. 2022 Dec 29;41 (1) :364.|J Exp Clin Cancer Res. 2025 Aug 27;44 (1) :255.|J Funct Foods. 2019, 103562.|J Hazard Mater. 2025 Nov 25:501:140617.|J Immunol Res. 2020 Feb 10;2020:6457879.|J Immunol. 2024 Jun 15;212 (12) :1877-1890.|J Immunother Cancer. 2018 Dec 18;6 (1) :151.|J Immunother Cancer. 2024 Oct 23;12 (10) :e010148.|J Immunother Cancer. 2019 Jul 12;7 (1) :178.|J Inflamm Res. 2021 Mar 23;14:1007-1017.|J Inflamm Res. 2025 Sep 29:18:13433-13452.|J Integr Agric. 2023 Feb 24.|J Interferon Cytokine Res. 2019 Apr;39 (4) :224-232. |J Interferon Cytokine Res. 2021 Dec;41 (12) :439-449.|J Invest Dermatol. 2019 Dec;139 (12) :2488-2496.e4.|J Invest Dermatol. 2022 Feb;142 (2) :303-313.e9.|J Invest Dermatol. 2022 Oct;142 (10) :2591-2602.e8.|J Leukoc Biol. 2023 Sep 1;114 (3) :266-279.|J Leukoc Biol. 2025 May 21:qiaf070.|J Lipid Res. 2024 Aug 16:100623.|J Microbiol. 2021 Aug;59 (8) :771-781.|J Mol Cell Cardiol. 2015 Dec;89 (Pt B) :268-79. |J Mol Histol. 2025 Jul 31;56 (4) :246.|J Nanobiotechnology. 2022 Mar 27;20 (1) :162.|J Nanobiotechnology. 2023 Sep 4;21 (1) :316.|J Nanobiotechnology. 2025 Jul 22;23 (1) :535.|J Neuroinflammation. 2020 Oct 28;17 (1) :321.|J Neuroinflammation. 2022 Nov 24;19 (1) :283.|J Neuroinflammation. 2024 Aug 2;21 (1) :192.|J Neuroinflammation. 2024 Jan 8;21 (1) :13.|J Neurol Sci. 2020 Mar 15;410:116679.|J Oral Pathol Med. 2024 May 19.|J Orthop Translat. 2025 Jun 18:53:112-125.|J Periodontol. 2020 Aug;91 (8) :1085-1097.|J Periodontol. 2022 Mar;93 (3) :e60-e72.|J Pharm Pharmacol. 2023 Jun 5;75 (6) :828-836.|J Pharmacol Exp Ther. 2025 Oct 8;392 (11) :103744.|J Physiol Sci. 2024 Oct 3;74 (1) :49.|J Proteome Res. 2021 May 7;20 (5) :2329-2339.|J Surg Res. 2024 Jul 22:301:413-422.|J Transl Med. 2019 Oct 4;17 (1) :335.|J Vet Med Sci. 2023 Jul 1;85 (7) :721-726.|J Vet Sci. 2023 Sep;24 (5) :e72.|J Virol. 2023 Jun 29;97 (6) :e0028423.|J Virol. 2024 Feb 20;98 (2) :e0194823.|J Virol. 2025 Aug 19;99 (8) :e0065525.|JCI Insight. 2025 Nov 25:e196605.|Josip Juraj Strossmayer University of Osijek. 2025.|Life Sci. 2020 Apr 1;246:117396.|Life Sci. 2020 Nov 15;261:118465.|Life Sci. 2024 Dec 1:358:123163.|Life Sci. 2024 Jun 22:122857.|Life Sci. 2025 Apr 23:123663.|Med Sci Monit. 2019 Jun 21:25:4609-4616.|Med Sci Monit. 2020 Aug 7:26:e925298.|MedComm. 2023 Jul 8;4 (4) :e320.|Mediators Inflamm. 2020 Nov 3;2020:8925973. |Microb Pathog. 2021 Oct:159:105136.|Microb Pathog. 2022 Jan:162:105219.|Mol Biol Rep. 2024 Nov 8;51 (1) :1134.|Mol Cell Biochem. 2022 Apr;477 (4) :1009-1022.|Mol Cell Biochem. 2025 May;480 (5) :3133-3145.|Mol Cell Endocrinol. 2018 Jul 15:470:38-47.|Mol Cell Endocrinol. 2019 Apr 5:485:35-43.|Mol Cell Toxicol (2019) 15:209-219|Mol Cell. 2020 Jan 2;77 (1) :95-107.e5.|Mol Immunol. 2017 Jul:87:161-170.|Mol Immunol. 2018 Nov:103:133-143.|Mol Immunol. 2021 Mar:131:97-111.|Mol Med Rep. 2019 Nov;20 (5) :4576-4586.|Mol Med Rep. 2020 Jul;22 (1) :566-574.|Mol Med Rep. 2021 Oct;24 (4) :709.|Mol Neurobiol. 2025 Jul;62 (7) :9290-9305.|Mol Nutr Food Res. 2019 Dec;63 (24) :e1900601.|Mol Ther Oncolytics. 2022 Aug 5:26:372-386.|Molecules. 2022 Feb 27;27 (5) :1577.|Mycopathologia. 2021 Jun;186 (3) :341-354.|Nanotoxicology. 2020 Jun;14 (5) :667-682. |Nat Commun. 2018 Apr 30;9 (1) :1723.|Nat Commun. 2024 Apr 11;15 (1) :3165.|Nat Commun. 2024 Oct 2;15 (1) :8540.|Nat Commun. 2025 Apr 16;16 (1) :3623.|Nat Commun. 2025 Mar 15;16 (1) :2565.|Nat Immunol. 2023 Nov;24 (11) :1813-1824.|Nat Metab. 2021 Oct;3 (10) :1357-1371.|Nat Metab. 2024 Apr;6 (4) :708-723.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 14.|Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398 (3) :3001-3014.|Neural Regen Res. 2023 Aug;18 (8) :1802-1808.|Neurochem Int. 2022 Jan:152:105221.|Neurochem Int. 2025 Oct:189:106024.|Neurochem Int. 2025 Sep 26:106061.|Neurochem Res. 2020 Sep;45 (9) :2052-2064.|Neurochem Res. 2024 Nov 19;50 (1) :21.|Neuropharmacology. 2025 Apr 16:110469.|Neuropsychiatry (London) . 2018;8 (4) ;1132-1139.|Neurosci Lett. 2024 Jan 18:820:137611.|Neuroscience. 2021 Apr 1:459:104-117.|Nitric Oxide. 2022 Dec 1:129:41-52.|Npg Asia Mater. (2019) 11:38|NPJ Parkinsons Dis. 2025 May 6;11 (1) :114.|Nutr Metab. 2021 Nov 21;18 (1) :100.|Oncogene. 2017 Apr;36 (15) :2095-2104.|Oncogene. 2022 Feb;41 (6) :907-919.|Oncogene. 2025 May;44 (16) :1078-1092.|Oncol Lett. 2020 Apr;19 (4) :3269-3277.|Oncotarget. 2017 Oct 19;8 (60) :101965-101983.|Oxid Med Cell Longev. 2017:2017:6175841.|Oxid Med Cell Longev. 2022 Jun 22:2022:2333848.|Oxid Med Cell Longev. 2022 Mar 10:2022:1863098.|Pak J Zool. 2023 Nov 17.|Parasit Vectors. 2021 Jul 8;14 (1) :358.|Patent. US20170349880A1.|Patent. US20180263995A1.|PeerJ. 2023 Aug 23:11:e15890.|Peptides. 2019 Sep:119:170120.|Pharmacogn Mag. 2025 May 27.|Pharmacol Res. 2018 Jul:133:218-235.|Pharmacol Res. 2025 May 6:107763.|Pharmacology. 2022;107 (1-2) :14-27.|Phytochemistry. 2020 Dec;180:112531.|Phytomedicine. 2018 Mar 15:42:152-163.|Phytomedicine. 2020 Mar;68:153146.|Phytomedicine. 2020 May 24;75:153247.|Phytomedicine. 2020 Nov;78:153306.|Phytomedicine. 2021 Mar:83:153479.|Phytomedicine. 2022 Apr:98:153928.|Phytomedicine. 2024 Dec:135:156052.|Phytomedicine. 2025 May 21:143:156891.|Phytother Res. 2023 Feb;37 (2) :689-701.|PLoS Biol. 2018 May 11;16 (5) :e2004225. |PLoS One. 2020 Sep 3;15 (9) :e0235824.|PLoS Pathog. 2024 Dec 9;20 (12) :e1012744.|PLoS Pathog. 2025 Oct 27;21 (10) :e1013623.|Poult Sci. 2024 Oct;103 (10) :104052.|Poult Sci. 2025 Oct 3;104 (12) :105940. |Programa de Doctorado en Biomedicina. 2020 Sep.|Protein Cell. 2019 Mar;10 (3) :161-177. |Redox Biol. 2023 Feb:59:102594.|Redox Biol. 30 August 2022, 102452.|Reprod Domest Anim. 2021 Aug;56 (8) :1066-1084.|Res Sq. 2024 Jun 19.|Res Sq. 2024 Oct 15.|Res Sq. 2025 Aug 08.|Research (Wash D C) . 2025.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2021 Jan.|Research Square Preprint. 2021 May.|Research Square Preprint. 2021 Oct.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2022 Feb.|Research Square Preprint. 2022 Jan.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Nov 10.|Research Square Preprint. 2024 Aug 21.|Research Square Preprint. 2024 Mar 29.|Research Square Print. November 15th, 2022|Research Square Print. November 29th, 2022.|Respir Res. 2021 Aug 3;22 (1) :216.|Respir Res. 2023 Apr 7;24 (1) :103.|School of Healthcare Science. Manchester Metropolitan University. 2017 May.|Sci Adv. 2025 Aug;11 (31) :eadu4270. |Sci Immunol. 2022 Jan 21;7 (67) :eabj5501.|Sci Rep. 2017 Oct 19;7 (1) :13571.|Sci Rep. 2022 Feb 23;12 (1) :3053.|Sci Rep. 2025 Nov 17;15 (1) :40227.|Sci Rep. 2025 Oct 21;15 (1) :36751.|Sci Total Environ. 2023 Dec 10:903:166449.|Signal Transduct Target Ther. 2020 Aug 25;5 (1) :163.|Signal Transduct Target Ther. 2022 Jul 11;7 (1) :222.|SSRN. 2023 May 8.|SSRN. 2024 Feb 15.|SSRN. 2025 Oct 9.|SSRN. 8 Nov 2021.|Stem Cell Res Ther. 2021 May 20;12 (1) :295.|Stem Cell Res Ther. 2022 Jan 21;13 (1) :22.|Stem Cell Rev Rep. 2022 Aug;18 (6) :2074-2087.|Stem Cells. 2020 Jan;38 (1) :134-145.|Stem Cells. 2022 May 27;40 (5) :508-522.|Stem Cells. 2022 Sep 26;40 (9) :857-869.|Tissue Cell. 2024 Jul 25:90:102496.|Toxicol Appl Pharmacol. 2019 Mar 1:366:83-95.|Toxicol Appl Pharmacol. 2019 Nov 1:382:114703.|Toxicol Appl Pharmacol. 2021 May 1:418:115484.|Toxicol Lett. 2023 Aug 1:384:73-85.|Toxicology. 2021 Apr 15:453:152721.|Toxicon. 2024 May 11:244:107757.|Toxics. 2022 May 27;10 (6) :285.|Toxics. 2024 Oct 25;12 (11) :779.|Toxins. 2021 Jun 13;13 (6) :422.|Toxins. 2022 Jan 1;14 (1) :29.|University of Minnesota. 2025.|Vaccines. 2019 Dec 14;7 (4) :216.|Vet Microbiol. 2021 May:256:109061.|Vet Microbiol. 2025 Sep 11:310:110726.|Vet Res. 2021 Oct 21;52 (1) :135.|Virology. 2017 Aug:508:150-158.|Washington State University. 2025.|Acta Pharm Sin B. 2023 Feb;13 (2) :722-738.|Anal Cell Pathol. 2022 Sep 27;2022:9358583.|Biochem Pharmacol. 2024 Mar:221:116047.|Cancer Res. 2022 May 16;82 (10) :1991-2002.|Cell Mol Life Sci. 2018 Jul;75 (14) :2627-2641.|Cell Mol Life Sci. 2023 Jun 21;80 (7) :186.|Food Chem X. 2022 Jan 15:13:100211.|Food Sci Anim Resour. 2022 Nov;42 (6) :942-952.|Front Pharmacol. 2021 May 18;12:644116.|Inflamm Res. 2025 Feb 19;74 (1) :42.|Int Immunopharmacol. 2024 Jun 15:134:112143.|Int J Cancer. 2018 Aug 1;143 (3) :645-656.|Int J Mol Sci. 2023 Jul 6;24 (13) :11168.|J Exp Clin Cancer Res. 2022 Sep 16;41 (1) :275.|J Neuroinflammation. 2018 Jun 15;15 (1) :184.|J Periodontal Res. 2022 Jan;57 (1) :195-204.|JOR Spine. 2024 Apr 17;7 (2) :e1325.|Life Sci. 2022 Feb 15:291:120258.|New Phytol. 2024 May 13.|Onco Targets Ther. 2021 Oct 22;14:5131-5144.|Phytother Res. 2025 Oct 6.|Research Square Print. 2022 Aug.|Research Square Print. September 20th, 2022.|Respir Res. 2022 Jan 11;23 (1) :6.|Viruses. 2022 Jul 2;14 (7) :1465.|Viruses. 2022 Jul 7;14 (7) :1485.

Chemical Information

Sb-203580

SB 203580 is a member of the class of imidazoles carrying 4-methylsulfinylphenyl, 4-pyridyl and 4-fluorophenyl substituents at positions 2, 4 and 5 respectively. An inhibitor of mitogen-activated protein kinase. It has a role as a geroprotector, an EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor, a neuroprotective agent, a Hsp90 inhibitor and an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor. It is a sulfoxide, a member of imidazoles, a member of pyridines and a member of monofluorobenzenes.

CAS Number152121-47-6
PubChem CID176155
IUPAC Name4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazol-5-yl]pyridine
Molecular FormulaC21H16FN3OS
Molecular Weight377.4
XLogP3.2
Topological Polar Surface Area77.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Heavy Atom Count27
Formal Charge0
Complexity500
SMILES
CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
InChI
InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25)
InChIKey
CDMGBJANTYXAIV-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Sb-203580
CAS: 152121-47-6
CID: 176155
Formula: C21H16FN3OS
MW: 377.4
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight377.4
XLogP33.2
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass377.09981148
Monoisotopic Mass377.09981148
Topological Polar Surface Area77.9 Ų
Heavy Atom Count27
Formal Charge0
Complexity500
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
BUP20653-01Adezmapimod
E4791-100mgAdezmapimod hydrochloride
C16092-100mgAdezmapimod (SB203580)
A10824-500Adezmapimod (SB-203580) 500mg
A10824-50Adezmapimod (SB-203580) 50mg

Popular Products